Yasuhiro Miyazaki

Yasuhiro Miyazaki

Auto-generated profile, based on publicly available information

Yasuhiro Miyazaki

Department of Surgery, Osaka General Medical Center, Osaka, Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2021 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
YMYasuhiro Miyazaki
Yasuhiro Miyazaki
TOTakeshi Omori
Takeshi Omori
KFKazumasa Fujitani
Kazumasa Fujitani
JFJunya Fujita
Junya Fujita
RKRyohei Kawabata
Ryohei Kawabata
OSOsaka University Clinical Research Group for Gastroenterological Study
Osaka University Clinical Research Group for Gastroenterological Study

26 October 2023 in Annals of Surgery
Verified
Journal Article
Open access
Ryota MatsuiRyota Matsui
Ryota Matsui
MSMasano Sagawa
Masano Sagawa
ASAkihiko Sano
Akihiko Sano
MSMakoto Sakai
Makoto Sakai
SHShin-ichiro Hiraoka
Shin-ichiro Hiraoka
JKJoji Kotani
Joji Kotani
Objective: To clarify whether perioperative immunonutrition is effective in adult patients with or without malnutrition undergoing elective surgery for head and neck (HAN) or gastrointestinal (GI) cancers. Background: It is important to avoid postoperative complications in patients with cancer as they can compromise clinical outcomes. There is no consensus on the efficacy of perioperative immunonutrition in patients with or without malnutrition undergoing HAN or GI cancer surgery. Materials and Methods: We searched MEDLINE (PubMed), MEDLINE (OVID), EMBASE, Cochrane Central Register of Controlled Trials, Web of Science Core Selection, and Emcare from 1981 to 2022 using search terms related to immunonutrition and HAN or GI cancer. We included randomized controlled trials. Intervention was defined as immunonutritional therapy including arginine, n-3 omega fatty acids, or glutamine during the perioperative period. The control was defined as standard nutritional therapy. The primary outcomes were total postoperative and infectious complications, defined as events with a Clavien–Dindo classification grade ≥ II that occurred within 30 days after surgery. Results: Of the 4825 patients from 48 included studies, 19 had upper GI cancer, 9 had lower, and 8 had mixed cancer, whereas 12 had HAN cancers. Immunonutrition reduced the total postoperative complications (relative risk ratio: 0.78; 95% CI, 0.66–0.93; certainty of evidence: high) and infectious complications (relative risk ratio: 0.71; 95% CI, 0.61–0.82; certainty of evidence: high) compared with standard nutritional therapy. Conclusions: Nutritional intervention with perioperative immunonutrition in patients with HAN and GI cancers significantly reduced total postoperative complications and infectious complications.

1 April 2022 in Clinical Nutrition
Verified
Journal Article
Closed access
MMMasaaki Motoori
Masaaki Motoori
KSKeijiro Sugimura
Keijiro Sugimura
KTKoji Tanaka
Koji Tanaka
OSOsamu Shiraishi
Osamu Shiraishi
YKYutaka Kimura
Yutaka Kimura
MYMasahiko Yano
Masahiko Yano

8 September 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
YKYusuke Kawachi
Yusuke Kawachi
FYFujishima Yuya
Fujishima Yuya
HNHitoshi Nishizawa
Hitoshi Nishizawa
TNTakashi Nakamura
Takashi Nakamura
SASeigo Akari
Seigo Akari
ISIichiro Shimomura
Iichiro Shimomura
Xanthine oxidoreductase (XOR) is an enzyme that catalyzes hypoxanthine to xanthine and xanthine to uric acid, respectively. However, the underlying mechanisms of increased plasma XOR and its pathological roles in systemic diseases, such as atherosclerosis, are not fully understood. In this study, we found that changes in plasma XOR activity after bariatric surgery closely associated with those in liver enzymes, but not with those in BMI. In a mouse model of nonalcoholic fatty liver disease/steatohepatitis (NAFLD/NASH), plasma XOR activity markedly increased. Besides, purine catabolism was accelerated in the plasma per se of NASH mice and human patients with high XOR activity. In our NASH mice, we observed an increased vascular neointima formation consisting of dedifferentiated vascular smooth muscle cells (SMCs), which was significantly attenuated by topiroxostat, a selective XOR inhibitor. In vitro, human liver S9–derived XOR promoted proliferation of SMCs with phenotypic modulation and induced ROS production by catabolizing hypoxanthine released from human endothelial cells. Collectively, the results from human and mouse models suggest that increased plasma XOR activity, mainly explained by excess hepatic leakage, was involved in the pathogenesis of vascular injury, especially in NAFLD/NASH conditions.

7 October 2011 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
SMS. Maeshima
S. Maeshima
AOA. Osawa
A. Osawa
YMY. Miyazaki
Y. Miyazaki
HTH. Takeda
H. Takeda
NTN. Tanahashi
N. Tanahashi

24 September 2012 in Surgery Today
Verified
Journal Article
Closed access
PDF file
KYKazuyoshi Yamamoto
Kazuyoshi Yamamoto
STShuji Takiguchi
Shuji Takiguchi
HMHiroshi Miyata
Hiroshi Miyata
YMYasuhiro Miyazaki
Yasuhiro Miyazaki
YHYuichiro Hiura
Yuichiro Hiura
YDYuichiro Doki
Yuichiro Doki